SCHEMBL15514971

SCHEMBL15514971

Cc1nccn1CC1CCN(C(=O)O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.52
OPRD1 P41143 1/20 0.42
PIM1 P11309 1/20 0.39
FDPS P14324 1/20 0.38
LDHA P00338 1/20 0.38
BRD4 O60885 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37
PLAA Q9Y263 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
HTR3E A5X5Y0 1/20 0.37
SLC22A2 O15244 1/20 0.37
SLC22A1 O15245 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948973 0.82 GPR119 (0.50) F10OPRD1KDM4E
SCHEMBL16419181 0.81 ALDH1A1 (0.48) F10PIM1FDPSBRD4KDM4E
SCHEMBL28192282 0.77 KDM4E (0.50) F10OPRD1PIM1BRD4KDM4E
SCHEMBL23204979 0.74 BRD4 (0.54) F10PIM1BRD4KDM4EALDH1A1
SCHEMBL1181466 0.74 BRD4 (0.55) F10PIM1FDPSBRD4KDM4E
Hydrochloric Acid SCHEMBL28784813 0.73 BRD4 (0.54) F10PIM1BRD4KDM4EALDH1A1
SCHEMBL15515146 0.72 NOTUM (0.37) BRD4HTR2B
SCHEMBL8544090 0.72 FAAH (0.51) F10OPRD1HTR2B
SCHEMBL1582097 0.72 MTNR1A (0.46)
SCHEMBL11983333 0.71 SMN1; SMN2 (0.47) KDM4EALPLALPIALPGPLAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10188642-B2 Pharmacologically active compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-01-29 US disclosed
US-20180117032-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-9895364-B2 Pharmacologically active compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-02-20 US disclosed
EP-2892890-B1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RES TECH LTD (GB) 2017-11-22 EP disclosed
US-20160296514-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2016-10-13 US disclosed
US-9334286-B2 Pharmacologically active compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-05-10 US disclosed
US-20150218181-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-08-06 US disclosed
EP-2892890-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS Cancer Research Technology Ltd (GB) 2015-07-15 EP disclosed
WO-2014037751-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218181-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS BUB1B, BUB1, PLK1 F10 4147/4885OPRD1 4091/4885PIM1 1458/4885
US-20180117032-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS BUB1B, BUB1, PLK1 F10 4147/4885OPRD1 4091/4885PIM1 1458/4885
US-10188642-B2 Pharmacologically active compounds BUB1B, BUB1, PLK1 F10 4147/4885OPRD1 4091/4885PIM1 1458/4885
US-20160296514-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS BUB1B, BUB1, PLK1 F10 4147/4885OPRD1 4091/4885PIM1 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.